KalVista Pharmaceuticals, Inc.
KALV
$13.24
-$0.17-1.27%
NASDAQ
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 15.89M | 12.59M | 16.61M | 26.61M | 25.25M |
| Gross Profit | -15.89M | -12.59M | -16.61M | -26.61M | -25.25M |
| SG&A Expenses | 39.14M | 30.35M | 29.20M | 17.60M | 23.21M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.03M | 42.94M | 45.81M | 44.22M | 48.46M |
| Operating Income | -55.03M | -42.94M | -45.81M | -44.22M | -48.46M |
| Income Before Tax | -53.08M | -44.26M | -42.27M | -40.44M | -44.65M |
| Income Tax Expenses | -855.00K | 4.25M | -- | -- | -- |
| Earnings from Continuing Operations | -52.23M | -48.51M | -42.27M | -40.44M | -44.65M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -52.23M | -48.51M | -42.27M | -40.44M | -44.65M |
| EBIT | -55.03M | -42.94M | -45.81M | -44.22M | -48.46M |
| EBITDA | -54.77M | -42.71M | -45.58M | -43.99M | -48.24M |
| EPS Basic | -0.98 | -0.92 | -0.91 | -0.87 | -1.02 |
| Normalized Basic EPS | -0.63 | -0.53 | -0.57 | -0.55 | -0.64 |
| EPS Diluted | -0.98 | -0.92 | -0.91 | -0.87 | -1.02 |
| Normalized Diluted EPS | -0.63 | -0.53 | -0.57 | -0.55 | -0.64 |
| Average Basic Shares Outstanding | 53.04M | 52.64M | 46.70M | 46.23M | 43.59M |
| Average Diluted Shares Outstanding | 53.04M | 52.64M | 46.70M | 46.23M | 43.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |